These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27477479)

  • 1. Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome.
    Katz-Agranov N; Padilla J; Scoon J; Cherian SV
    Ann Hematol; 2016 Oct; 95(11):1923-4. PubMed ID: 27477479
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma.
    Cai X; Bhattacharyya S; Plitt A; Raibagkar P; LaBuzetta JN; Schleicher SM; Munshi NC; Klein JP
    J Clin Oncol; 2016 Jan; 34(2):e1-5. PubMed ID: 24799479
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
    Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
    Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
    Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
    Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose carfilzomib proteasome inhibition induces anemia by oxidative hemolysis: A case series of 8 patients from a single centre.
    Rajagopal R; Bennett R; Liang J; Royle G
    Am J Hematol; 2019 Aug; 94(8):E215-E216. PubMed ID: 31066096
    [No Abstract]   [Full Text] [Related]  

  • 8. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma-All That Glitters Is Not Gold.
    Hashmi H; Shah Z; Anwer F
    JAMA Oncol; 2021 Jul; 7(7):967-968. PubMed ID: 33792618
    [No Abstract]   [Full Text] [Related]  

  • 12. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience.
    Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G
    Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 17. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations.
    Sonneveld P
    JAMA Oncol; 2015 Sep; 1(6):754-5. PubMed ID: 26181637
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.